Preclinical research in Abu Dhabi uses AI to help design compounds that remove a protein associated with some blood cancers
Research published in the Journal of Medicinal Chemistry explores AI-supported compounds designed to remove a protein associated with some blood cancers. Researchers from Insilico Medicine investigated compounds targeting Bruton’s tyrosine kinase, known as BTK, which supports signalling involved in the survival of malignant B cells. The approach uses molecules designed to recruit a cell’s own protein disposal machinery, removing BTK through targeted degradation rather than simply inhibiting its activity.
Insilico says its Chemistry42 generative AI platform helped design molecular components. The team evaluated more than 40 compounds and identified two leads with activity in laboratory models and oral bioavailability in mice. The results remain preclinical and do not establish safety or effectiveness in people. “Our ambition in Abu Dhabi is to build a team that can originate new medicines,” said Alex Aliper, President of Insilico Medicine.
The findings point to a stage of pharmaceutical development where computational design and experimental chemistry need to work together. A model can propose a promising structure, but researchers must still establish how a compound behaves and whether its characteristics justify further investigation.
For healthcare innovation policy, the local capability is a separate consideration from the eventual success of an individual medicine. Research teams able to design and test new compounds can contribute scientific knowledge even when a project does not ultimately produce a clinical treatment.
A laboratory finding may provide a reason to continue development, while the evidence required to support treatment decisions lies much further along the research pathway.
The next scientific questions concern whether the lead compounds can progress through additional testing and retain useful properties as development continues. Any later clinical programme would need to examine outcomes in patients.
For Abu Dhabi, the publication provides a concrete example of locally conducted drug discovery work. Its immediate contribution is to the research evidence, with possible therapeutic applications still dependent on subsequent investigation and clinical development.
Have some thoughts on the topic? Share them with the community here